Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Charbonnel

Showing results (1-10 of 60) with videos related to

Pageof 6
Sort By:
Fundamental & Clinical Pharmacology|November 16, 2007
Glitazones in the treatment of diabetes mellitus: clinical outcomes in large scale clinical trialsBernard Charbonnel
La Revue Du Praticien|December 21, 2005
[Metabolic syndrome and cardiovascular risk]Bernard Charbonnel
La Revue Du Praticien|May 15, 2010
[Is the metabolic syndrome still a useful entity?]Bernard Charbonnel
Expert Opinion on Investigational Drugs|November 10, 2015
Sotagliflozin as a potential treatment for type 2 diabetes mellitusBertrand Cariou, Bernard Charbonnel
Journal of Diabetes|October 7, 2010
Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20)Erland Erdmann, Robert Spanheimer, Bernard Charbonnel, et al.
Hospital Practice (1995)|May 18, 2013
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?Bernard Charbonnel, Anja Schweizer, Sylvie Dejager
Trends in Endocrinology and Metabolism: TEM|April 20, 2012
Thiazolidinediones and PPARγ agonists: time for a reassessmentBertrand Cariou, Bernard Charbonnel, Bart Staels
Current Cardiology Reviews|August 3, 2010
Thiazolidinediones and cardiovascular risk - a question of balanceErland Erdmann, Bernard Charbonnel, Robert Wilcox
Presse Medicale (Paris, France : 1983)|June 21, 2011
[Sugar-sweetened beverages and cardiometabolic risk]Jean Dallongeville, Bernard Charbonnel, Jean-Pierre Desprès
Current Medical Research and Opinion|September 12, 2015
Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitusAnthony H Barnett, Bernard Charbonnel, Robert G Moses, et al.
Pageof 6

Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
Fundamental & Clinical Pharmacology|November 16, 2007
Glitazones in the treatment of diabetes mellitus: clinical outcomes in large scale clinical trialsBernard Charbonnel
La Revue Du Praticien|December 21, 2005
[Metabolic syndrome and cardiovascular risk]Bernard Charbonnel
La Revue Du Praticien|May 15, 2010
[Is the metabolic syndrome still a useful entity?]Bernard Charbonnel
Expert Opinion on Investigational Drugs|November 10, 2015
Sotagliflozin as a potential treatment for type 2 diabetes mellitusBertrand Cariou, Bernard Charbonnel
Journal of Diabetes|October 7, 2010
Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20)Erland Erdmann, Robert Spanheimer, Bernard Charbonnel, et al.
Hospital Practice (1995)|May 18, 2013
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?Bernard Charbonnel, Anja Schweizer, Sylvie Dejager
Trends in Endocrinology and Metabolism: TEM|April 20, 2012
Thiazolidinediones and PPARγ agonists: time for a reassessmentBertrand Cariou, Bernard Charbonnel, Bart Staels
Current Cardiology Reviews|August 3, 2010
Thiazolidinediones and cardiovascular risk - a question of balanceErland Erdmann, Bernard Charbonnel, Robert Wilcox
Presse Medicale (Paris, France : 1983)|June 21, 2011
[Sugar-sweetened beverages and cardiometabolic risk]Jean Dallongeville, Bernard Charbonnel, Jean-Pierre Desprès
Current Medical Research and Opinion|September 12, 2015
Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitusAnthony H Barnett, Bernard Charbonnel, Robert G Moses, et al.
Pageof 6